Breaking: Numis Reiterates GBX 2967.00 Price Objective On Croda International PLC (LON:CRDA) Shares, Reiterates Their Original Hold Rating

Share

Croda International PLC (LON:CRDA) Rating Reaffirmed

They currently have a GBX 2967.00 target price per share on Croda International PLC (LON:CRDA). The target price by Numis would suggest a potential upside of 1.85% from the company’s last price. This has been disclosed in analysts note on Wednesday morning.

From a total of 18 analysts covering Croda International PLC (LON:CRDA) stock, 6 rate it a ”Buy”, 2 a “Sell”, and 9 a ”Hold”. This means that 35% of the ratings are positive. The highest target price is GBX 3400 while the lowest target price is GBX 1800. The mean of all analyst targets is GBX 2927.06 with a 3.71% above today’s (GBX 2909) stock price. Croda International PLC was the topic of 35 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Societe Generale maintained shares on December 2 with “Buy” rating. Investec maintained shares with “Hold” rating and GBX 2800 target share price in a report from a November 26. Morgan Stanley maintained CRDA stock in a recent report from December 1 with “Overwt/In-Line” rating. UBS maintained the rating on November 25. UBS has a “Sell” rating and a GBX 2350 price target on shares. Finally, Goldman Sachs maintained the stock with “Buy” rating in a report issued on a November 30.

Approximately 26,669 shares of stock traded hands. Croda International Plc (LON:CRDA) has risen 3.12% since May 5, 2015 and is uptrending. It has outperformed by 3.32% the S&P500.

Breaking: Numis Reiterates GBX 2967.00 Price Objective On Croda International PLC (LON:CRDA) Shares, Reiterates Their Original Hold Rating

Croda International Plc is a United Kingdom specialty chemical manufacturer. The company has a market cap of 3.95 billion GBP. The Company’s divisions include Personal Care, Life Sciences, Performance Technologies and Industrial Chemicals. It has 22.61 P/E ratio. The Firm is a supplier of specialty ingredients for the personal care industry.

COMMENTS: